Azenta, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AZTA in the last 30 days.
See all $AZTA insider activity →Azenta (AZTA) will close three Multiomics lab sites in North America to streamline operations and improve efficiency, according to a company announcement. The move is part of a restructuring plan approved by the board.
Pacific Biosciences (PACB), Fortrea (FTRE), Alamar (ALMR), 10x Genomics (TXG), and Azenta (AZTA) reached 52-week highs on October 6, 2026. PACB announced a collaboration with TychoBio, FTRE reported Q2 revenue of $678M, ALMR saw Q2 revenue surge to $29.43M, TXG launched the Atera platform, and AZTA reported 12% Q3 revenue growth.
Azenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning AZTA (Azenta, Inc.). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.
Recent AZTA coverage spans corporate actions, earnings and financial news.
The lab closures signal a cost‑cutting move that may reduce near‑term revenue but could improve long‑term margins.
The stock may see limited upside as the rally could stall.
Recap of already‑public earnings; no new driver.
Strong quarterly results reinforce growth narrative, likely sustaining price gains.
Potential impact on governance and future strategic direction.
AlphAI scores every news story that mentions AZTA with an AI model for sentiment and relevance, and aggregates insider trades from Azenta, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Azenta (AZTA) will close three Multiomics lab sites in North America to streamline operations and improve efficiency, according to a company announcement. The move is part of a restructuring plan approved by the board.
1 min readPacific Biosciences (PACB), Fortrea (FTRE), Alamar (ALMR), 10x Genomics (TXG), and Azenta (AZTA) reached 52-week highs on October 6, 2026. PACB announced a collaboration with TychoBio, FTRE reported Q2 revenue of $678M, ALMR saw Q2 revenue surge to $29.43M, TXG launched the Atera platform, and AZTA reported 12% Q3 revenue growth.
2 min readAzenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.
2 min readCareDx (CDNA), AVITA Medical (RCEL), Azenta (AZTA), and Hinge Health (HNGE) reached 52-week highs on October 2, 2026. CDNA reported $132M Q2 revenue, up 52% YoY. RCEL saw 18% Q2 revenue growth. AZTA reported 12% Q3 revenue growth. HNGE saw 53% Q2 revenue growth and acquired Cylinder Health for $105M.
2 min readAzenta, Inc. (AZTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers.
1 min readAzenta (AZTA) granted its interim CEO, Martin D. Madaus, 36,653 restricted stock units (RSUs) on September 14, 2026. The RSUs vest monthly over 12 months and will settle in common stock, increasing Madaus' direct holdings to 44,058 shares. No payment was made for the grant, and no Rule 10b5-1 trading plan is reported.
1 min readAzenta (AZTA) announced full repayment of a $35M vendor loan related to the sale of B Medical Systems. The loan, secured by B Medical Systems' equity, was repaid early with interest. This completes the $63M divestiture, with Azenta receiving the full purchase price in cash. The company's CEO highlighted the completion of the transaction and the retirement of associated credit exposure.
1 min readAzenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.
3 min readBMF Reports argues SELLAS Life Sciences (SLS) is overvalued due to unclear Phase 3 trial data, predicting 76% downside if it fails. Fugazi Research claims TEN Holdings (XHLD) is a pump-and-dump scheme. A Value Investors’ Club author warns Charter Communications (CHTR) faces debt and competition risks. Notable executive departures include D-Wave Quantum (QBTS), Azenta (AZTA), Amrize (AMRZ), GE Vernova (GEV), and Tesla (TSLA).
2 min readAzenta (AZTA) announced CEO John Marotta's resignation and appointed Dr. Martin Madaus as interim CEO. The company reaffirmed its Q4 2026 revenue guidance of 3-5% growth. Analysts discuss potential impacts on margins and profitability during the leadership transition.
2 min read
